Company: Solid Biosciences Inc.
Symbol: SLDB
Description: Their mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.
Shares: 5.89 million
Price Range: $16.00-$18.00
Trade Date: 1/25
Underwriter(s): J.P. Morgan, Goldman Sachs & Co., Leerink Partners
Co-Manager(s): Nomura, Chardan
Terms Added: 1-16-18
Business: Their lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients’ muscles. Based on their preclinical program that included multiple animal species of different phenotypes and genetic variations, they believe the mechanism of action of SGT-001, if their clinical trials prove to be successful, has the potential to slow or even halt the progression of DMD, regardless of the type of genetic mutation or stage of the disease.
Insider Buying: Certain of their existing stockholders have indicated an interest in purchasing an aggregate of approximately $40.0 million of shares of our common stock in this offering at the initial public offering price.
Collaboration & License Agreement: This company has licensing agreements with the University of Washington, University of Missouri, University of Michigan and Harvard College. Additionally, in 2016, they entered into a license agreement with Life Technologies Corporation, or Life Technologies. In consideration for obtaining a non-exclusive, royalty-free, worldwide license to use certain technologies and associated know-how to develop their product candidates, we paid a one-time, non-refundable license fee.
Patents: They have exclusively licensed three issued U.S. patents, one pending U.S. non-provisional patent application, and seven issued patents and eleven pending patent applications in foreign jurisdictions. They have filed two pending U.S. provisional patent applications. We intend to continue building out our intellectual property protection to further strengthen our position in the DMD field.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish